SCHEMBL24899993

SCHEMBL24899993

O=C(O)N1C2CCC1COC2

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28273390 0.91 MEN1 (0.32)
SCHEMBL3710945 0.81 CHRM2 (0.31)
SCHEMBL16824955 0.79
SCHEMBL26906075 0.79 CHRM2 (0.35)
SCHEMBL20958513 0.79 CHRM2 (0.35)
SCHEMBL25226842 0.79
SCHEMBL26919745 0.79 CHRM2 (0.35)
SCHEMBL23149394 0.79 CHRM2 (0.35)
SCHEMBL21413597 0.78 VNN1 (0.32) VNN1
SCHEMBL17572101 0.78 SMN1; SMN2 (0.42) VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4303216-A1 FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2024-01-10 EP disclosed
WO-2023288028-A2 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR JANSSEN BIOTECH, INC. (US) 2023-01-19 WO disclosed
WO-2023288017-A2 BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR JANSSEN BIOTECH, INC. (US) 2023-01-19 WO disclosed